ArticlePLoS genetics2020
The genomic landscape of metastasis in treatment-naïve breast cancer models.
Article in PLoS genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Insights from Genomic Sequencing of Preclinical Breast Cancer Models Establish Human Parallels to Increase Therapeutic Applicability.Journal of mammary gland biology and neoplasia · 2026Review
- Genetic background and oncogenic driver determines the genomic evolution and transcriptomics of mammary tumor metastasis.Communications biology · 2025Article
- Expression of Wnt/β-Catenin Pathway Markers in Ascites Tumor Cells in Ovarian Cancer.Bulletin of experimental biology and medicine · 2025Article
- Investigating the genomic landscape of mouse models of breast cancer metastasis.bioRxiv : the preprint server for biology · 2025Article
- SMARCD1 is an essential expression-restricted metastasis modifier.Communications biology · 2024Article
- Resf1 is a compound G4 quadruplex-associated tumor suppressor for triple negative breast cancer.PLoS genetics · 2024Article
- SMARCD1 is a "Goldilocks" metastasis modifier.bioRxiv : the preprint server for biology · 2024Article
- Article
- Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.Breast cancer research : BCR · 2023Article
- RHAMM regulates MMTV-PyMT-induced lung metastasis by connecting STING-dependent DNA damage sensing to interferon/STAT1 pro-apoptosis signaling.Breast cancer research : BCR · 2023Article
- Molecular Characterization and Landscape of Breast cancer Models from a multi-omics Perspective.Journal of mammary gland biology and neoplasia · 2023Review
- Characterization of Mammary Tumors Arising from MMTV-PyVT Transgenic Mice.Current issues in molecular biology · 2023Article
- Cancer metastasis chemoprevention prevents circulating tumour cells from germination.Signal transduction and targeted therapy · 2022Review
- Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH.PLoS genetics · 2022Article
- Stromal p53 Regulates Breast Cancer Development, the Immune Landscape, and Survival in an Oncogene-Specific Manner.Molecular cancer research : MCR · 2022Article
- Nuclear pore protein NUP210 depletion suppresses metastasis through heterochromatin-mediated disruption of tumor cell mechanical response.Nature communications · 2021Article
- Modeling metastasis in mice: a closer look.Trends in cancer · 2021Review
- Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo.Oncogene · 2021Review
- Methodological Advancements for Investigating Intra-tumoral Heterogeneity in Breast Cancer at the Bench and Bedside.Journal of mammary gland biology and neoplasia · 2020Article
- Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures.Molecular cancer research : MCR · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Metastasis remains the principle cause of mortality for breast cancer and presents a critical challenge because secondary lesions are often refractory to conventional treatments. While specific genetic alterations are tightly linked to primary tumor development and progression, the role of genetic alteration in the metastatic process is not well-understood. The theory of tumor evolution postulated by Peter Nowell in 1976 has yet to be proven in the context of metastasis. Therefore, in order to investigate how somatic evolution contributes to breast cancer metastasis, we performed exome, whole genome, and RNA sequencing of matched metastatic and primary tumors from pre-clinical mouse models of breast cancer. Here we show that in a treatment-naïve setting, recurrent single nucleotide variants and copy number variation, but not gene fusion events, play key metastasis-driving roles in breast cancer. For instance, we identified recurrent mutations in Kras, a known driver of colorectal and lung tumorigenesis that has not been previously implicated in breast cancer metastasis. However, in a set of in vivo proof-of-concept experiments we show that the Kras G12D mutation is sufficient to significantly promote metastasis using three syngeneic allograft models. The work herein confirms the existence of metastasis-driving mutations and presents a novel framework to identify actionable metastasis-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.